PCM
RLYB icon

Prelude Capital Management’s Rallybio RLYB Stock Holding History

Prelude Capital Management’s Portfolio RLYB Stock Details RLYB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		– Sell
-1,725
Closed -$18.5K – 1500
2024
Q2 		$18.5K Buy
+1,725
New +$23.4K ﹤0.01% 1175

Other funds holding RLYB

Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return
JJ
Johnson & Johnson New Brunswick, New Jersey $652M AUM 198.07% 1-Year Est. Return
5VM
5AM Venture Management San Francisco, California $360M AUM 345.76% 1-Year Est. Return
NLVP
New Leaf Venture Partners New York $43M AUM 25.55% 1-Year Est. Return
TGA
TPG GP A Fort Worth, Texas $3.68B AUM 14.99% 1-Year Est. Return
PBPIA
Pivotal bioVenture Partners Investment Advisor San Francisco, California $280M AUM 181.4% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
CPX
Canaan Partners XI Menlo Park, California $76.1M AUM 638.59% 1-Year Est. Return
Aberdeen Group
Aberdeen Group Edinburgh, United Kingdom $61.9B AUM 29.81% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Prelude Capital Management's RLYB Position: Q3 2024 in Review

Prelude Capital Management sold out of Rallybio (RLYB) in Q3 2024, closing a stake of 1,725 shares — an estimated $18.5K sold.

Prelude Capital Management first reported a position in RLYB in Q2 2024 and held it in 1 quarter. The position peaked at $18.5K in Q2 2024. 49 funds tracked by Wall St. Rank hold RLYB as of Q3 2024.

  • Prelude Capital Management reported no remaining Rallybio position as of Q3 2024 after selling out during the quarter.
  • Prelude Capital Management sold 1,725 Rallybio shares in Q3 2024, an estimated $18.5K.
  • Prelude Capital Management first reported a position in Rallybio in Q2 2024 and held it in 1 quarter.
  • Prelude Capital Management's Rallybio position peaked at $18.5K in Q2 2024.
  • 49 funds tracked by Wall St. Rank held Rallybio as of Q3 2024.

Based on Prelude Capital Management's 13F filing for Q3 2024, filed 14 Nov 2024.